Medical Science Liaison
UroGen Pharma, Inc
Medical Science Liaison
UroGen Pharma, Inc
Develops RTGel-based drug delivery for uro-oncology
We offer a competitive salary, employee benefits, and an excellent work environment.
We are an Equal Opportunity Employer
Develops RTGel-based drug delivery for uro-oncology
UroGen Pharma develops RTGel-based drug-delivery therapies for urothelial and specialty cancers, commercializing products like Jelmyto and ZUSDURI and advancing a pipeline that includes UGN-102, UGN-103, UGN-104, and UGN-301. Its RTGel platform is liquid at cool temperatures and gels at body temperature, allowing chemotherapy to stay at the treatment site longer for local, sustained exposure. The company differentiates itself by delivering established chemotherapy directly to the disease site to reduce systemic exposure and by building a multi-product portfolio focused on urothelial cancers. Its goal is to improve local treatment outcomes and grow a diversified, globally commercial portfolio through ongoing clinical development and partnerships.
Explore more opportunities at UroGen Pharma, Inc